|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DE4013632A1
(de)
|
1990-04-27 |
1991-10-31 |
Max Planck Gesellschaft |
Liposomen mit positiver ueberschussladung
|
|
DE69740107D1
(de)
|
1996-12-23 |
2011-03-10 |
Immunex Corp |
Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
|
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
US6274338B1
(en)
|
1998-02-24 |
2001-08-14 |
President And Fellows Of Harvard College |
Human c-Maf compositions and methods of use thereof
|
|
DE60021254T2
(de)
|
1999-03-15 |
2006-04-20 |
AXYS Pharmaceuticals, Inc., South San Francisco |
N-cyanomethylamide als protease inhibitoren
|
|
DE60132975T2
(de)
|
2000-01-06 |
2009-02-26 |
Merck Frosst Canada Inc., Kirkland |
Neue substanzen und verbindungen als protease-inhibitoren
|
|
EP2295081B1
(en)
|
2001-06-26 |
2018-10-31 |
Amgen Inc. |
Antibodies to OPGL
|
|
AR036375A1
(es)
|
2001-08-30 |
2004-09-01 |
Novartis Ag |
Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
|
|
GB0121033D0
(en)
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
|
KR100485271B1
(ko)
|
2002-01-16 |
2005-04-27 |
메타볼랩(주) |
전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
|
|
SE0201980D0
(sv)
|
2002-06-24 |
2002-06-24 |
Astrazeneca Ab |
Novel compounds
|
|
DE10235624A1
(de)
|
2002-08-02 |
2004-02-19 |
Aventis Pharma Deutschland Gmbh |
Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
|
|
WO2004063355A2
(en)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
|
|
WO2005029067A2
(en)
|
2003-09-24 |
2005-03-31 |
Oncotherapy Science, Inc. |
Method of diagnosing breast cancer
|
|
WO2005046731A1
(en)
|
2003-10-17 |
2005-05-26 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Interference with c-maf function in multiple myeloma
|
|
WO2005060722A2
(en)
|
2003-12-18 |
2005-07-07 |
President And Fellows Of Hardvard College |
Modulation of immune system function by modulation of polypeptide arginine methyltransferases
|
|
TW200526224A
(en)
|
2003-12-22 |
2005-08-16 |
Alcon Inc |
Short form c-Maf transcription factor antagonists for treatment of glaucoma
|
|
JP2007527247A
(ja)
|
2004-03-05 |
2007-09-27 |
ロゼッタ インファーマティクス エルエルシー |
臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類
|
|
US20080131940A1
(en)
|
2004-06-25 |
2008-06-05 |
Robert Chiu |
Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
|
|
WO2006135436A2
(en)
|
2004-10-22 |
2006-12-21 |
University Of Florida Research Foundation, Inc. |
Inhibition of gene expression and therapeutic uses thereof
|
|
US9134237B2
(en)
|
2005-09-20 |
2015-09-15 |
Janssen Diagnotics, LLC |
High sensitivity multiparameter method for rare event analysis in a biological sample
|
|
CA2623405C
(en)
|
2005-09-20 |
2014-11-25 |
Immunivest Corporation |
Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes
|
|
JP2009509966A
(ja)
|
2005-09-26 |
2009-03-12 |
ノバルティス アクチエンゲゼルシャフト |
骨転移に関連した分子マーカー
|
|
WO2008098351A1
(en)
|
2007-02-14 |
2008-08-21 |
University Health Network |
Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
|
|
EP1961825A1
(en)
|
2007-02-26 |
2008-08-27 |
INSERM (Institut National de la Santé et de la Recherche Medicale) |
Method for predicting the occurrence of metastasis in breast cancer patients
|
|
CA2687903C
(en)
|
2007-05-24 |
2016-09-13 |
Ablynx N.V. |
Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
|
|
EP2155905A1
(en)
|
2007-05-31 |
2010-02-24 |
Dako Denmark A/S |
Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
|
|
NZ562237A
(en)
|
2007-10-05 |
2011-02-25 |
Pacific Edge Biotechnology Ltd |
Proliferation signature and prognosis for gastrointestinal cancer
|
|
WO2009049410A1
(en)
|
2007-10-18 |
2009-04-23 |
University Health Network |
Clioquinol for the treatment of hematological malignancies
|
|
WO2009114534A1
(en)
|
2008-03-14 |
2009-09-17 |
The Regents Of The University Of California |
Multi-gene classifiers and prognostic indicators for cancers
|
|
WO2009146546A1
(en)
|
2008-06-06 |
2009-12-10 |
University Health Network |
8-hydroxyquinoline derivatives for the treatment of hematological malignancies
|
|
ES2338843B1
(es)
|
2008-07-02 |
2011-01-24 |
Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas |
Huella genomica de cancer de mama.
|
|
US8642270B2
(en)
|
2009-02-09 |
2014-02-04 |
Vm Institute Of Research |
Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
|
|
CN102421448A
(zh)
|
2009-05-29 |
2012-04-18 |
霍夫曼-拉罗奇有限公司 |
Her2信号传导调控剂在表达her2的胃癌患者中
|
|
EP2486149B1
(en)
|
2009-08-06 |
2015-06-17 |
John Wayne Cancer Institute |
Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
|
|
EP3517630B1
(en)
*
|
2010-10-06 |
2022-01-19 |
Institució Catalana de Recerca i Estudis Avançats |
Method for the diagnosis, prognosis and treatment of breast cancer metastasis
|
|
US20140162887A1
(en)
|
2011-02-04 |
2014-06-12 |
Bioarray Therapeutics, Inc. |
Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
|
|
EP2685988A4
(en)
|
2011-03-15 |
2014-08-20 |
Univ North Carolina |
Methods of treating breast cancer with anthracycline therapy
|
|
US20140303133A1
(en)
|
2011-11-18 |
2014-10-09 |
Vanderbilt University |
Markers of Triple-Negative Breast Cancer And Uses Thereof
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
EP3467124A1
(en)
|
2012-06-06 |
2019-04-10 |
Fundació Institut de Recerca Biomèdica IRB (Barcelona) |
Method for the diagnosis, prognosis and treatment of lung cancer metastasis
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
KR101872965B1
(ko)
|
2012-10-12 |
2018-06-29 |
인바이오모션 에스.엘. |
Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
|
|
JP6577873B2
(ja)
|
2013-03-15 |
2019-09-18 |
フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） |
がんの転移の予後診断および処置のための方法
|
|
CA2903306A1
(en)
|
2013-03-15 |
2014-09-18 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the diagnosis, prognosis and treatment of metastatic cancer
|
|
WO2014184679A2
(en)
*
|
2013-03-15 |
2014-11-20 |
Inbiomotion S.L. |
Method for the prognosis and treatment of renal cell carcinoma metastasis
|
|
TR201907389T4
(tr)
*
|
2013-10-09 |
2019-06-21 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
|
|
KR20170093182A
(ko)
|
2014-12-11 |
2017-08-14 |
인바이오모션 에스.엘. |
인간 c-maf에 대한 결합 구성원
|
|
AU2017271385B2
(en)
|
2016-05-25 |
2023-10-05 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-MAF status
|
|
EP3296431A1
(en)
|
2016-09-15 |
2018-03-21 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Method of synthesis of an electrode for use as a catalyst of oxygen evolution reaction
|
|
MX2020005182A
(es)
|
2017-11-22 |
2020-08-17 |
Inbiomotion Sl |
Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
|